Literature DB >> 22497817

End-stage renal disease and African American race are independent predictors of mild liver fibrosis in patients with chronic hepatitis C infection.

F M Aslinia1, S K Wasan, A L Mindikoglu, O A Adeyemo, B Philosophe, C Drachenberg, C D Howell.   

Abstract

Recipients of haemodialysis for end-stage renal disease (ESRD) have a higher prevalence of hepatitis C virus (HCV) infection relative to the general US population. However, the natural course of HCV infection in patients with renal failure, including African Americans (AAs) and Caucasian Americans (CAs), is not well known. We compared the degree of liver inflammation and fibrosis in AA and CA patients with HCV infection, with and without ESRD. This was a cross-sectional study of 156 HCV patients with ESRD (130 AAs and 26 CAs) with a liver biopsy between 1992 and 2005. The control group consisted of 138 patients (50 AAs; 88 CAs) with HCV infections and a serum creatinine <1.5 mg/dL with a liver biopsy between 1995 and 1998. Specimens were graded for inflammation and fibrosis using Knodell histological activity index. Compared to patients without renal impairment, HCV patients with renal failure were older and more likely to be AA. Patients with renal impairment had lower mean serum transaminases, a higher mean serum alkaline phosphatase levels (all P < 0.0001) and less hepatic necro-inflammation (Knodell histological activity index -I, II and III; P < 0.05) and fibrosis (Knodell histological activity index -IV; P < 0.0001). There were no racial differences in serum liver chemistry and histology scores among patients with renal failure. In a multivariate analysis, younger age, ESRD, AA race and a lower serum alkaline phosphatase were associated with lower odds for advanced liver fibrosis. Thus, HCV patients with ESRD had a lower degree of hepatic inflammation and fibrosis compared to those without renal disease, independent of race.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22497817      PMCID: PMC3328295          DOI: 10.1111/j.1365-2893.2011.01565.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  25 in total

1.  Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor.

Authors:  T Rampino; E Arbustini; M Gregorini; P Guallini; C Libetta; M Maggio; A Ranghino; E Silini; G Soccio; A Dal Canton
Journal:  Kidney Int       Date:  1999-12       Impact factor: 10.612

2.  Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

Authors:  T Poynard; V Ratziu; F Charlotte; Z Goodman; J McHutchison; J Albrecht
Journal:  J Hepatol       Date:  2001-05       Impact factor: 25.083

3.  Histopathological features of hepatitis C in renal transplant candidates [see comment].

Authors:  P Martin; D Carter; F Fabrizi; V Dixit; A J Conrad; L Artinian; V Peacock; S Han; A Wilkinson; C R Lassman; G Danovitch
Journal:  Transplantation       Date:  2000-04-15       Impact factor: 4.939

4.  Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy.

Authors:  Eijun Nakayama; Takashi Akiba; Fumiaki Marumo; Chifumi Sato
Journal:  J Am Soc Nephrol       Date:  2000-10       Impact factor: 10.121

5.  Hepatitis C infection in African Americans: its natural history and histological progression.

Authors:  Thelma E Wiley; Jennifer Brown; Juliana Chan
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

6.  Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation.

Authors:  R K Sterling; A J Sanyal; V A Luketic; R T Stravitz; A L King; A B Post; A S Mills; M J Contos; M L Shiffman
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

7.  Characteristics of hepatitis C in renal transplant candidates.

Authors:  Scott J Cotler; Gloria Diaz; Sushama Gundlapalli; Shiram Jakate; Anshuman Chawla; Deepak Mital; Steven Jensik; Donald M Jensen
Journal:  J Clin Gastroenterol       Date:  2002-08       Impact factor: 3.062

Review 8.  Hepatitis C infection and the patient with end-stage renal disease.

Authors:  Fabrizio Fabrizi; F Fred Poordad; Paul Martin
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

9.  Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study.

Authors:  M Wright; R Goldin; A Fabre; J Lloyd; H Thomas; C Trepo; P Pradat; M Thursz
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

10.  Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

Authors:  L Castéra; C Hézode; F Roudot-Thoraval; A Bastie; E-S Zafrani; J-M Pawlotsky; D Dhumeaux
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

View more
  2 in total

Review 1.  Hepatitis C in hemodialysis patients.

Authors:  Smaragdi Marinaki; John N Boletis; Stratigoula Sakellariou; Ioanna K Delladetsima
Journal:  World J Hepatol       Date:  2015-03-27

2.  Serum hyaluronic acid in chronic viral hepatitis B and C: a biomarker for assessing liver fibrosis in chronic hemodialysis patients.

Authors:  Olga Hilda Orăşan; Mădălina Sava; Mihaela Iancu; Angela Cozma; Aniela Saplonţai-Pop; Simina Sarlea Ţărmure; Corneliu Lungoci; Remus Aurel Orăşan; Ioan Mihai Patiu; Dan Lucian Dumitraşcu
Journal:  Int Urol Nephrol       Date:  2015-05-30       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.